HIV-1 infects and kills a specific group of white blood cells called "CD4 T- 
lymphocytes." This damage to the body's immune system leaves the infected individual 
susceptible to infections and cancers. 
Other white blood cells, called "cytotoxic T-lymphocytes" (CTL), are believed to be 
important "killers" of cells infected with viruses. Thus, HIV-infected individuals could 
theoretically benefit from a treatment that stimulates these CTL and also produces more 
antibodies that are able to inactivate the virus. 
HIV-IT (V) has been shown to specifically stimulate both CTL and antibody 
immune responses in mice and non-human primates. The Treatment has not produced 
toxic side effects in these animals. 
The treatment involves the direct injection of a specially engineered non-disease 
producing virus (the "viral vector") that is disabled and contains the gene for a small 
portion of the HIV virus. 
PROCEDURES 
A. Screening Evaluation . Only adult male or female individuals who are proven to 
be infected with HIV-1 and have CD4 counts greater than 400, who are free of 
AIDS-related symptoms, and who are healthy enough to participate in everyday 
activities can be selected for the study. Before I take part in the actual study, the 
Investigator will perform a screening evaluation to determine whether I meet all 
the criteria for participation. This two day evaluation includes a medical 
history, physical examination, urine, blood and skin tests. To conduct the skin 
test, a device will be pressed against the lower inside portion of my arm to 
insert a panel of tiny needles, just below my skin, containing standard skin test 
substances. Two days later my arm will be examined for temporary reactions 
(small bumps) to help determine whether my immune system reacts strongly 
enough to these substances to allow me to enroll in the study. A 100 ml blood 
sample (about one-half cup) will be drawn at the second visit to evaluate my 
general condition, my immune system and the level of HIV in my system. 
B . Exclusion . Even if I meet the qualifications for participation in the Study, I will 
not be allowed to take part if (1) I am unwilling to use reliable barrier birth 
control methods that would block HIV transmission, or (2) I am a woman who 
is pregnant or is breast-feeding, or (3) the Investigator determines that I have 
significant medical problems other than HIV-1 infection. In addition, the 
[916] 
Recombinant DNA Research, Volume 17 
